Sight Sciences (SGHT) Stock Forecast, Price Target & Predictions
SGHT Stock Forecast
Sight Sciences stock forecast is as follows: an average price target of $10.25 (represents a 72.27% upside from SGHT’s last price of $5.95) and a rating consensus of 'Hold', based on 7 wall street analysts offering a 1-year stock forecast.
SGHT Price Target
The average price target for Sight Sciences (SGHT) is $10.25 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $6.00. This represents a potential 72.27% upside from SGHT's last price of $5.95.
SGHT Analyst Ratings
According to 7 Wall Street analysts, Sight Sciences's rating consensus is 'Hold'. The analyst rating breakdown for SGHT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (28.57%), 5 'Hold' (71.43%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Sight Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 04, 2024 | Frank Takkinen | Loop Capital Markets | $10.00 | $5.81 | 72.12% | 68.07% |
| Aug 21, 2024 | Frank Takkinen | Lake Street | $10.00 | $6.08 | 64.47% | 68.07% |
| May 03, 2024 | Matt O'Brien | Piper Sandler | $6.00 | $5.70 | 5.26% | 0.84% |
| Dec 12, 2022 | - | Citigroup | $15.00 | $12.65 | 18.58% | 152.10% |
| Aug 11, 2022 | Matt O'Brien | Piper Sandler | $15.00 | $9.81 | 52.91% | 152.10% |
The latest Sight Sciences stock forecast, released on Oct 04, 2024 by Frank Takkinen from Loop Capital Markets, set a price target of $10.00, which represents a 72.12% increase from the stock price at the time of the forecast ($5.81), and a 68.07% increase from SGHT last price ($5.95).
Sight Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 3 |
| Avg Price Target | $10.00 | $10.00 | $8.67 |
| Last Closing Price | $5.95 | $5.95 | $5.95 |
| Upside/Downside | 68.07% | 68.07% | 45.71% |
In the current month, the average price target of Sight Sciences stock is $10.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 68.07% increase as opposed to Sight Sciences's last price of $5.95. This month's average price target is down 0.00% compared to last quarter, and up 15.34% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 04, 2024 | Lake Street | Buy | Buy | Hold |
| Aug 21, 2024 | Lake Street | - | Buy | Initialise |
| Jul 15, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jul 10, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 03, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Sep 12, 2023 | William Blair | - | Market Perform | Downgrade |
| Sep 12, 2023 | Piper Sandler | Overweight | Neutral | Downgrade |
| Jan 06, 2023 | Stifel Nicolaus | - | Buy | Upgrade |
| Dec 12, 2022 | Citigroup | Buy | Buy | Hold |
| Oct 11, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
Sight Sciences's last stock rating was published by Lake Street on Oct 04, 2024. The company gave SGHT a "Buy" rating, the same as its previous rate.
Sight Sciences Financial Forecast
Sight Sciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $18.75M | $20.01M | $23.47M | $18.82M | $20.54M | $18.68M | $17.23M | $14.88M | $14.69M | $13.10M | $12.54M |
| Avg Forecast | $24.68M | $23.36M | $23.44M | $21.06M | $21.12M | $20.40M | $21.34M | $18.40M | $18.95M | $21.59M | $22.40M | $18.87M | $20.26M | $17.68M | $16.21M | $13.28M | $14.17M | $12.07M | $12.48M |
| High Forecast | $24.68M | $23.36M | $23.44M | $21.06M | $21.12M | $20.59M | $21.34M | $18.40M | $20.39M | $21.59M | $22.40M | $18.87M | $20.26M | $17.68M | $16.21M | $13.28M | $14.17M | $12.07M | $12.48M |
| Low Forecast | $24.68M | $23.36M | $23.44M | $21.06M | $21.12M | $20.19M | $21.34M | $18.40M | $17.50M | $21.59M | $22.40M | $18.87M | $20.26M | $17.68M | $16.21M | $13.28M | $14.17M | $12.07M | $12.48M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 0.99% | 0.93% | 1.05% | 1.00% | 1.01% | 1.06% | 1.06% | 1.12% | 1.04% | 1.09% | 1.00% |
Sight Sciences's average Quarter revenue forecast for Mar 24 based on 1 analysts is $18.40M, with a low forecast of $18.40M, and a high forecast of $18.40M. SGHT's average Quarter revenue forecast represents a -1.89% decrease compared to the company's last Quarter revenue of $18.75M (Dec 23).
Sight Sciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-10.92M | $-13.41M | $-13.40M | $-15.78M | $-15.67M | $-20.90M | $-22.57M | $-22.03M | $-27.73M | $-15.41M | $-16.36M |
| Avg Forecast | $-23.19M | $-21.95M | $-22.02M | $-19.80M | $-19.85M | $-19.17M | $-20.06M | $-17.29M | $-17.81M | $-20.29M | $-21.05M | $-17.73M | $-19.04M | $-16.62M | $-15.24M | $-12.48M | $-13.32M | $-11.35M | $-14.73M |
| High Forecast | $-23.19M | $-21.95M | $-22.02M | $-19.80M | $-19.85M | $-18.97M | $-20.06M | $-17.29M | $-16.45M | $-20.29M | $-21.05M | $-17.73M | $-19.04M | $-16.62M | $-15.24M | $-12.48M | $-13.32M | $-11.35M | $-11.78M |
| Low Forecast | $-23.19M | $-21.95M | $-22.02M | $-19.80M | $-19.85M | $-19.35M | $-20.06M | $-17.29M | $-19.17M | $-20.29M | $-21.05M | $-17.73M | $-19.04M | $-16.62M | $-15.24M | $-12.48M | $-13.32M | $-11.35M | $-17.67M |
| Surprise % | - | - | - | - | - | - | - | - | 0.61% | 0.66% | 0.64% | 0.89% | 0.82% | 1.26% | 1.48% | 1.76% | 2.08% | 1.36% | 1.11% |
undefined analysts predict SGHT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Sight Sciences's previous annual EBITDA (undefined) of $NaN.
Sight Sciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-10.69M | $-13.04M | $-14.75M | $-17.07M | $-16.91M | $-22.23M | $-23.84M | $-23.26M | $-20.08M | $-17.17M | $-17.61M |
| Avg Forecast | $-8.48M | $-9.35M | $-9.78M | $-10.17M | $-9.21M | $-10.35M | $-14.79M | $-13.78M | $-15.85M | $-15.86M | $-17.05M | $-19.53M | $-20.81M | $-22.86M | $-23.15M | $-20.04M | $-19.54M | $-13.13M | $-15.86M |
| High Forecast | $-8.48M | $-9.35M | $-9.78M | $-10.17M | $-9.21M | $-6.75M | $-14.79M | $-13.78M | $-9.05M | $-15.86M | $-17.05M | $-19.53M | $-20.81M | $-22.86M | $-23.15M | $-20.04M | $-19.54M | $-13.13M | $-12.69M |
| Low Forecast | $-8.48M | $-9.35M | $-9.78M | $-10.17M | $-9.21M | $-13.96M | $-14.79M | $-13.78M | $-19.92M | $-15.86M | $-17.05M | $-19.53M | $-20.81M | $-22.86M | $-23.15M | $-20.04M | $-19.54M | $-13.13M | $-19.03M |
| Surprise % | - | - | - | - | - | - | - | - | 0.67% | 0.82% | 0.87% | 0.87% | 0.81% | 0.97% | 1.03% | 1.16% | 1.03% | 1.31% | 1.11% |
Sight Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SGHT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Sight Sciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $23.47M | $26.50M | $30.06M | $28.68M | $28.70M | $31.54M | $31.43M | $28.39M | $26.41M | $20.79M | $17.76M |
| Avg Forecast | $36.99M | $35.01M | $35.13M | $31.57M | $31.66M | $30.58M | $31.99M | $27.57M | $28.40M | $32.36M | $33.58M | $28.28M | $30.36M | $26.50M | $24.30M | $19.91M | $21.24M | $18.10M | $18.70M |
| High Forecast | $36.99M | $35.01M | $35.13M | $31.57M | $31.66M | $30.86M | $31.99M | $27.57M | $30.57M | $32.36M | $33.58M | $28.28M | $30.36M | $26.50M | $24.30M | $19.91M | $21.24M | $18.10M | $18.70M |
| Low Forecast | $36.99M | $35.01M | $35.13M | $31.57M | $31.66M | $30.26M | $31.99M | $27.57M | $26.23M | $32.36M | $33.58M | $28.28M | $30.36M | $26.50M | $24.30M | $19.91M | $21.24M | $18.10M | $18.70M |
| Surprise % | - | - | - | - | - | - | - | - | 0.83% | 0.82% | 0.90% | 1.01% | 0.95% | 1.19% | 1.29% | 1.43% | 1.24% | 1.15% | 0.95% |
Sight Sciences's average Quarter SG&A projection for Mar 24 is $27.57M, based on 1 Wall Street analysts, with a range of $27.57M to $27.57M. The forecast indicates a 17.50% rise compared to SGHT last annual SG&A of $23.47M (Dec 23).
Sight Sciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.22 | $-0.27 | $-0.30 | $-0.35 | $-0.35 | $-0.46 | $-0.50 | $-0.49 | $-0.42 | $-0.43 | $-0.42 |
| Avg Forecast | $-0.17 | $-0.19 | $-0.20 | $-0.20 | $-0.18 | $-0.21 | $-0.30 | $-0.28 | $-0.32 | $-0.32 | $-0.34 | $-0.39 | $-0.42 | $-0.46 | $-0.46 | $-0.40 | $-0.39 | $-0.26 | $-0.02 |
| High Forecast | $-0.17 | $-0.19 | $-0.20 | $-0.20 | $-0.18 | $-0.14 | $-0.30 | $-0.28 | $-0.18 | $-0.32 | $-0.34 | $-0.39 | $-0.42 | $-0.46 | $-0.46 | $-0.40 | $-0.39 | $-0.26 | $-0.02 |
| Low Forecast | $-0.17 | $-0.19 | $-0.20 | $-0.20 | $-0.18 | $-0.28 | $-0.30 | $-0.28 | $-0.40 | $-0.32 | $-0.34 | $-0.39 | $-0.42 | $-0.46 | $-0.46 | $-0.40 | $-0.39 | $-0.26 | $-0.02 |
| Surprise % | - | - | - | - | - | - | - | - | 0.69% | 0.85% | 0.88% | 0.89% | 0.84% | 1.00% | 1.08% | 1.22% | 1.07% | 1.63% | 18.95% |
According to undefined Wall Street analysts, Sight Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SGHT previous annual EPS of $NaN (undefined).
Sight Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RPID | Rapid Micro Biosystems | $0.87 | $8.00 | 819.54% | Hold |
| FNA | Paragon 28 | $5.50 | $11.50 | 109.09% | Buy |
| NPCE | NeuroPace | $6.39 | $12.88 | 101.56% | Buy |
| CVRX | CVRx | $8.10 | $15.83 | 95.43% | Buy |
| OFIX | Orthofix Medical | $15.89 | $31.00 | 95.09% | - |
| LUNG | Pulmonx | $6.41 | $12.25 | 91.11% | Buy |
| SGHT | Sight Sciences | $5.95 | $10.25 | 72.27% | Hold |
| SIBN | SI-BONE | $12.81 | $20.00 | 56.13% | Buy |
| CNMD | CONMED | $64.72 | $96.00 | 48.33% | Buy |
| KIDS | OrthoPediatrics | $26.86 | $39.60 | 47.43% | Buy |
| VREX | Varex Imaging | $12.10 | $17.00 | 40.50% | Buy |
| AVNS | Avanos Medical | $23.61 | $27.00 | 14.36% | Hold |
| TCMD | Tactile Systems | $14.25 | $16.00 | 12.28% | Buy |
| AORT | Artivion | $26.73 | $30.00 | 12.23% | Buy |
SGHT Forecast FAQ
Is Sight Sciences a good buy?
No, according to 7 Wall Street analysts, Sight Sciences (SGHT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 28.57% of SGHT's total ratings.
What is SGHT's price target?
Sight Sciences (SGHT) average price target is $10.25 with a range of $6 to $15, implying a 72.27% from its last price of $5.95. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Sight Sciences stock go up soon?
According to Wall Street analysts' prediction for SGHT stock, the company can go up by 72.27% (from the last price of $5.95 to the average price target of $10.25), up by 152.10% based on the highest stock price target, and up by 0.84% based on the lowest stock price target.
Can Sight Sciences stock reach $9?
SGHT's average twelve months analyst stock price target of $10.25 supports the claim that Sight Sciences can reach $9 in the near future.
What is Sight Sciences's current price target trend?
1 Wall Street analyst forecast a $10 price target for Sight Sciences (SGHT) this month, up 68.07% from its last price of $5.95. Compared to the last 3 and 12 months, the average price target increased by 68.07% and increased by 45.71%, respectively.
What are Sight Sciences's analysts' financial forecasts?
Sight Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $81.26M (high $81.45M, low $81.05M), average EBITDA is $-76.37M (high $-76.173M, low $-76.549M), average net income is $-48.127M (high $-44.525M, low $-51.728M), average SG&A $121.81M (high $122.09M, low $121.49M), and average EPS is $-0.964 (high $-0.892, low $-1.037). SGHT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $92.54M (high $92.54M, low $92.54M), average EBITDA is $-86.967M (high $-86.967M, low $-86.967M), average net income is $-37.795M (high $-37.795M, low $-37.795M), average SG&A $138.71M (high $138.71M, low $138.71M), and average EPS is $-0.757 (high $-0.757, low $-0.757).
Did the SGHT's actual financial results beat the analysts' financial forecasts?
Based on Sight Sciences's last annual report (Dec 2023), the company's revenue was $81.06M, which missed the average analysts forecast of $81.8M by -0.91%. Apple's EBITDA was $-56.629M, missing the average prediction of $-76.88M by -26.34%. The company's net income was $-55.547M, missing the average estimation of $-68.293M by -18.66%. Apple's SG&A was $108.25M, missing the average forecast of $122.62M by -11.72%. Lastly, the company's EPS was $-1.14, missing the average prediction of $-1.369 by -16.70%. In terms of the last quarterly report (Dec 2023), Sight Sciences's revenue was $18.75M, missing the average analysts' forecast of $18.95M by -1.03%. The company's EBITDA was $-10.92M, missing the average prediction of $-17.806M by -38.67%. Sight Sciences's net income was $-10.691M, missing the average estimation of $-15.846M by -32.53%. The company's SG&A was $23.47M, missing the average forecast of $28.4M by -17.36%. Lastly, the company's EPS was $-0.22, missing the average prediction of $-0.318 by -30.72%